Walgreens Boots Alliance, Inc. (WBA) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: while there are positive aspects like growth in certain segments and strategic initiatives, challenges such as declining free cash flow, gross margin impact, and uncertainties in guidance persist. The Q&A section highlights management's cautious approach due to ongoing industry challenges and lack of specific guidance, which tempers optimism. Overall, the stock is likely to remain stable in the short term.
Key Financial Performance
Adjusted Earnings Per Share (EPS) $0.63, decreased 37% year-over-year due to lower sale leaseback gains, a challenging U.S. retail environment, and recent pharmacy trends.
Sales Growth 2.5% growth on a constant currency basis, with U.S. retail pharmacy increasing 2.3%, International up 1.6%, and U.S. Healthcare delivering 7.6% growth.
GAAP Net Loss $5.6 billion, compared to a loss of $2.9 billion in the first nine months of fiscal 2023, impacted by non-cash impairment charges related to VillageMD goodwill.
Comparable Sales (U.S. Retail Pharmacy) 3.5% growth year-on-year driven by brand inflation and pharmacy volume, but offset by a decline in retail sales.
Adjusted Operating Income (AOI) Decreased 48% year-over-year, with approximately 70% of the decline related to lower sale leaseback gains and reduced incentive accruals.
Pharmacy Comp Sales Increased 5.7%, driven by brand inflation and volume growth, with comp scripts excluding immunization growing 1.7%.
Comparable Retail Sales Declined 2.3% in the quarter due to a challenging consumer backdrop and a sustained pullback in discretionary spending.
International Sales Growth 1.6% growth, with Boots U.K. increasing 1.6% and Germany Wholesale up 4.9%.
U.S. Healthcare Sales $2.1 billion, increased 8% compared to the prior year quarter, with VillageMD sales of $1.6 billion growing 7% year-on-year.
Free Cash Flow Down by approximately $1.1 billion versus the prior year, impacted by legal payments and annuity premium contributions.
Capital Expenditures Declined by $497 million versus the first nine months of fiscal 2023, with expectations to achieve a year-over-year reduction of $600 million.
Adjusted EBITDA (U.S. Healthcare) $23 million, an improvement of $136 million compared to last year, driven by rightsizing costs and improved productivity.
Operating Highlights
New Product Launches: We are reevaluating our assortment to ensure its relevancy, leveraging select partners and our own brands. This means we will work with fewer partners who are helping us win.
Digital and Omnichannel Offerings: We are accelerating our digital and omnichannel offerings to meet our customers when, where and how they want to engage.
Market Positioning: We are in active discussions with our PBM and payer partners to align incentives and ensure we are paid fairly.
International Market Performance: Boots U.K. delivered meaningful retail comp growth and achieved another sequential quarter of market share gains from strength in both physical and digital channels.
Operational Efficiencies: We are committed to achieving $1 billion in cost savings this year.
Store Footprint Optimization: We are finalizing a multifactor store footprint optimization program which we expect will include the closure of a significant portion of underperforming stores over the next three years.
Strategic Review: We have launched a strategic and operational review to simplify and focus our business, leveraging our customer relationships to grow in capital-efficient ways.
Investment in Pharmacy Talent: We are partnering with critical stakeholders to help advance our work environment and make WBA the practice setting destination of choice for pharmacy talent.
Risk or Challenges
U.S. Retail Pharmacy Challenges: Significant challenges in the U.S. Retail Pharmacy business due to a worse than expected consumer environment and challenging pharmacy industry trends.
Consumer Behavior: Customers have become increasingly selective and price sensitive, impacting sales and profitability.
Pharmacy Industry Pressures: Increased regulatory and reimbursement pressures, fluctuations in NADAC pricing, and a growing but underperforming script market are negatively affecting pricing dynamics.
Store Performance: Plans to close a significant portion of underperforming stores, which may disrupt customer access and service.
Pharmacy Margin Headwinds: Continued pressures on pharmacy margins due to brand mix impacts, reimbursement pressure, and lower overall market growth.
Legal and Pension Payments: Operating cash flow negatively impacted by $785 million in legal payments and $386 million in pension contributions.
Economic Factors: Strain on lower-income consumers due to accumulated inflation and depleted savings, affecting overall consumer spending.
Cost Management: While cost-saving initiatives are in place, they are not sufficient to offset the declines in sales and profitability.
Guidance & Outlook
Strategic Review: Launched a strategic and operational review to simplify and focus the business, leveraging customer relationships to grow in capital-efficient ways, and identifying opportunities for profitable growth.
Store Footprint Optimization: Finalizing a multifactor store footprint optimization program, which may include the closure of a significant portion of underperforming stores over the next three years.
Customer Experience Enhancements: Investing in enhancing customer experience through assortment reevaluation, digital and omnichannel offerings, and improving pharmacy services.
Partnerships and Talent Development: Partnering with pharmacy schools to enhance the pharmacy labor supply chain and investing in pharmacy services to attract more patients.
Focus on Core Assets: Evaluating non-retail pharmacy assets for strategic fit and profit growth potential, with a commitment to invest in Boots UK and VillageMD.
Adjusted EPS Guidance: Lowered fiscal 2024 adjusted EPS guidance to $2.80 to $2.95, reflecting a challenging U.S. consumer environment and pharmacy margin pressures.
Retail Comp Sales Outlook: Expect fiscal 2024 retail comp sales to be down approximately 3%.
Pharmacy Margin Expectations: Anticipate continued pharmacy margin headwinds due to generic launches, NADAC fluctuations, and lower overall market growth.
Fiscal 2025 Considerations: Expect profitability growth in U.S. healthcare and international segments, but anticipate ongoing pharmacy headwinds.
Cost Savings Initiatives: On track to deliver $1 billion in cost savings this year, with a year-over-year reduction of $600 million in capital expenditures.
Shareholder Return Plan
Share Repurchase Program: The company is focused on generating meaningful cash flow and strengthening its strategically-relevant businesses, but no specific share buyback program was mentioned in the call.
Key Q&A
Earnings Word Cloud
WBA Transcript
The earnings call presents a mixed picture: strong sales growth across segments and improved free cash flow are positive, but the decline in adjusted EPS and operating income, alongside challenges in retail sales, cast a shadow. The Q&A session reveals management's reluctance to provide specific guidance on key metrics, which may concern investors. However, optimistic guidance on reimbursement pressure and healthcare subsegments, along with strategic initiatives like MFCs, balance the sentiment. Given these mixed signals, the stock price is likely to remain neutral over the next two weeks.
The earnings call revealed several negative indicators: a lowered EPS guidance, anticipated pharmacy margin headwinds, and a decline in retail sales. The Q&A highlighted ongoing uncertainties, including a multiyear turnaround plan and unclear timelines for stabilization. Despite some positive elements like net debt reduction and improved gross margins, the overall sentiment remains negative due to the challenging environment and lack of clear guidance, suggesting a potential stock price decline of -2% to -8%.
The earnings call reveals mixed signals: while there are positive aspects like growth in certain segments and strategic initiatives, challenges such as declining free cash flow, gross margin impact, and uncertainties in guidance persist. The Q&A section highlights management's cautious approach due to ongoing industry challenges and lack of specific guidance, which tempers optimism. Overall, the stock is likely to remain stable in the short term.
WBA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
